In Vivo Base Editing for Familial Hypercholesterolemia: Early Evidence from a Phase 1 Trial
A phase 1 trial of YOLT-101 gene therapy demonstrated sustained reductions in PCSK9 and LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia, though larger studies are required to establish clinical efficacy.